PHILADELPHIA – A purchaser of securities in a specialty health care solutions company alleges he and class members were damaged by a decline in the value of the securities.
Alexandre Pelletier filed a complaint on behalf of himself and all others similarly situated on Nov. 14 in the U.S. District Court for the Eastern District of Pennsylvania against Endo International PLC, et al. alleging violation of federal securities laws.
According to the complaint, the defendants announced in September 2015 that they had completed an acquisition of Par Pharmaceutical Holdings Inc. The plaintiff alleges the defendants failed to disclose that Par Pharmaceutical "had colluded with several of its industry peers to fix generic drug prices."
The plaintiff alleges the defendant's share prices fell in November 2016 after media outlets reported U.S. prosecutors were considering filing charges against Par Pharmaceutical and again in March 2017 when the defendants reported a net loss of $3.35 billion.
The plaintiff demands a jury trial and seeks pay damages, interest, court costs and any further relief the court grants. He is represented by Vincent A. Coppola of Pribanic and Pribanic LLC in Pittsburgh and Jeremy A. Lieberman and by Pomerantz LLP in New York and Chicago.
U.S. District Court for the Eastern District of Pennsylvania case number 2:17-cv-05114-JP